Huoluo Xiaoling Pellet promotes microglia M2 polarization through increasing MCPIP1 expression for ischemia stroke alleviation

被引:3
|
作者
Shen, Wei [1 ]
Wang, Xiaoguang [2 ]
Tang, Meiqi [3 ]
Yao, Lan [3 ]
Wan, Chenyu [4 ]
Niu, Jianli [5 ]
Kolattukudy, Pappachan E. [5 ]
Jin, Zhuqing [6 ]
机构
[1] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Chinese Med, 54 Youdian Rd, Hangzhou 310000, Peoples R China
[2] Xiamen Univ, Sch Life Sci, 4221-120 Xiangan North Rd, Xiamen 361100, Peoples R China
[3] Zhejiang Univ, Dept Chem, 38 Zheda Rd, Hangzhou 310027, Peoples R China
[4] Hangzhou Normal Univ, Affiliated Hosp, 126 Wenzhou Rd, Hangzhou 310015, Peoples R China
[5] Univ Cent Florida, Burnett Sch Biomed Sci, Coll Med, 4000 Cent Florida Blvd, Orlando, FL USA
[6] Zhejiang Chinese Med Univ, Sch Basic Med Sci, 548 Binwen Rd, Hangzhou 310053, Peoples R China
基金
中国国家自然科学基金;
关键词
Huoluo Xiaoling Pellet (HXP); Ischemia stroke; MCPIP1; Microglia; M2; polarization; INFLAMMATORY MECHANISMS;
D O I
10.1016/j.biopha.2023.114914
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Huoluo Xiaoling Pellet (HXP), a Chinese patent medicine, is commonly administered for the treatment of treat ischemic strokes. MCPIP1, an inducible suppressor of the inflammatory response, is a regulator of microglial M2 polarization. This study aimed to explore whether HXP can promote microglial M2 polarization by upregulating MCPIP1 expression, consequently mitigating cerebral ischemic injury. Our study involved 85 Sprague-Dawley rats (weighing 250-280 g). We established middle cerebral artery occlusion (MCAO) and oxygen-glucose deprivation-reoxygenation (OGD/R) models with MCPIP1 knockdown to assess the effects of HXP on ischemic strokes. Our findings show that HXP reduced brain water content, improved neurological function, and inhibited the expression of inflammatory factors in the brain tissues of MCAO rats. The neuroprotective effects of HXP on cerebral ischemic injuries were compromised by MCPIP1 knockdown. Immunofluorescence results indicated that the expression of microglia marker Iba1 and M2 phenotypic marker CD206 was upregulated in MCAO rats and OGD/R-treated microglia. Administration of HXP significantly reduced Iba1 expression and facilitated CD206 expression, an effect that was counteracted by sh-MCPIP1 transfection. Western blotting revealed that HXP treatment augmented the expression of MCPIP1, microglial M2 marker proteins (CD206 and Arg1), and PPAR gamma, while reducing the expression of microglial M1 marker proteins (CD16 and iNOS) in MCAO rats and OGD/Rinduced microglia. MCPIP1 knockdown suppressed HXP-mediated upregulation of MCPIP1, CD206, Arg1, and PPAR gamma, as well as the downregulation of CD16 and iNOS. Our findings suggest that HXP primarily ameliorates ischemic stroke through the upregulation of MCPIP1, which in turn induces microglial M2 polarization.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Runx1 Deficiency Promotes M2 Macrophage Polarization Through Enhancing STAT6 Phosphorylation
    Siyuan Zhou
    Ting Zhao
    Xuqiong Chen
    Wuwen Zhang
    Xiaoyi Zou
    Yi Yang
    Qinshi Wang
    Ping Zhang
    Tong Zhou
    Tongbao Feng
    Inflammation, 2023, 46 : 2241 - 2253
  • [32] Runx1 Deficiency Promotes M2 Macrophage Polarization Through Enhancing STAT6 Phosphorylation
    Zhou, Siyuan
    Zhao, Ting
    Chen, Xuqiong
    Zhang, Wuwen
    Zou, Xiaoyi
    Yang, Yi
    Wang, Qinshi
    Zhang, Ping
    Zhou, Tong
    Feng, Tongbao
    INFLAMMATION, 2023, 46 (06) : 2241 - 2253
  • [33] Pioglitazone Modulates Microglia M1/M2 Polarization Through PPAR-γ Pathway and Exerts Neuroprotective Effects in Experimental Subarachnoid Hemorrhage
    Ding, Yingying
    Wang, Yue
    Qi, Ming
    Zhang, Xu
    Wu, Da
    MOLECULAR NEUROBIOLOGY, 2024, : 5930 - 5946
  • [34] Electroacupuncture Improves Learning and Memory Impairment in Rats with Cerebral Ischemia/Reperfusion Injury by Promoting Microglia/Macrophage M2 Polarization Through Nrf2/HO-1 Pathway
    Xiao, Yuqian
    Bai, Yanjie
    Sun, Kexin
    Wan, Jun
    Chen, Limin
    Chen, Shuying
    Wang, Yan
    Li, Wenjing
    Liu, An
    JOURNAL OF INFLAMMATION RESEARCH, 2025, 18 : 2925 - 2941
  • [35] Silencing BMAL1 promotes M1/M2 polarization through the LDHA/lactate axis to promote GBM sensitivity to bevacizumab
    Wang, Fan
    Liao, Wenjun
    Li, Caiyan
    Zhu, Ling
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 134
  • [36] Ultrasound reduces inflammation by modulating M1/M2 polarization of microglia through STAT1/STAT6/PPARγ signaling pathways
    Hsu, Chin-Hung
    Pan, Yi-Ju
    Zheng, Yin-Ting
    Lo, Raymond Y.
    Yang, Feng-Yi
    CNS NEUROSCIENCE & THERAPEUTICS, 2023, 29 (12) : 4113 - 4123
  • [37] TREM2 promotes hippocampal neurogenesis through regulating microglial M2 polarization in APP/PS1 mice
    Peng, Xiao-Qian
    Guo, Hong-Song
    Zhang, Xiao
    Wu, Xiang-Yuan
    Ruganzu, John Bosco
    Wu, Song-Di
    Zhao, Ming-Tao
    Li, Lei
    Yang, Yang
    Ji, Sheng-Feng
    Yang, Wei-Na
    Ren, Peng-Yu
    EXPERIMENTAL NEUROLOGY, 2025, 388
  • [38] Cysteinyl Leukotriene Receptor 2 is Involved in Inflammation and Neuronal Damage by Mediating Microglia M1/M2 Polarization through NF-κB Pathway
    Zhao, Rui
    Ying, Miaofa
    Gu, Shenglong
    Yin, Wei
    Li, Yanwei
    Yuan, Hong
    Fang, Sanhua
    Li, Mingxing
    NEUROSCIENCE, 2019, 422 : 99 - 118
  • [39] MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression
    Lin, Jinti
    Xu, Ankai
    Jin, Jiakang
    Zhang, Man
    Lou, Jianan
    Qian, Chao
    Zhu, Jian
    Wang, Yitian
    Yang, Zhengming
    Li, Xiumao
    Yu, Wei
    Liu, Bing
    Tao, Huimin
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [40] Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy
    Liang, Xisong
    Wang, Zeyu
    Dai, Ziyu
    Zhang, Hao
    Zhang, Jian
    Luo, Peng
    Liu, Zaoqu
    Liu, Zhixiong
    Yang, Kui
    Cheng, Quan
    Zhang, Mingyu
    CANCER GENE THERAPY, 2023, 30 (03) : 481 - 496